UK parliamentary scrutiny of obesity and weight-loss policy

The Health and Social Care Select Committee has issued critical reports regarding the United Kingdom’s approach to obesity and the distribution of weight-loss medications.

Initially, the committee criticized the NHS rollout of GLP-1 drugs, such as Mounjaro, describing it as ‘unambitious’. MPs warned that limited availability has fostered a ‘two-tier system’ based on wealth, which deepens health inequalities. To mitigate this, the committee recommended a summit on drug access, better integration of digital providers, and a crackdown on the black market for unlicensed medications.

Following this, the committee expressed a lack of faith in the government’s broader 10-year obesity strategy. While the plan includes measures like junk food advertising restrictions and bans on high-caffeine energy drinks for minors, the committee noted significant delays in key areas such as nutrient profiling models. Committee chairwoman Layla Moran stated that the current lack of a cohesive plan risks appearing ‘naïve at best, or insincere at worst’, prompting calls for the Prime Minister to establish clearly defined targets and milestones.